HUTCHMED (China) Ltd
H7T1
Company Profile
Business description
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 21218200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,970
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
4 factors that led to the incredible returns of Philip Morris.
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,055.30 | 34.60 | -0.43% |
| CAC 40 | 8,171.47 | 56.90 | 0.70% |
| DAX 40 | 23,288.06 | 92.64 | -0.40% |
| Dow JONES (US) | 41,964.63 | 383.32 | 0.92% |
| FTSE 100 | 8,706.66 | 1.43 | 0.02% |
| HKSE | 24,771.14 | 30.57 | 0.12% |
| NASDAQ | 17,750.79 | 246.67 | 1.41% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,111.93 | 66.00 | 0.55% |
| S&P 500 | 5,675.29 | 60.63 | 1.08% |
| S&P/ASX 200 | 7,828.30 | 32.10 | -0.41% |
| SSE Composite Index | 3,426.43 | 3.33 | -0.10% |